Ray Dalio's ALNY Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 85,617 shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $34.05 M, representing 0.12% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in ALNY, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 51,706 shares. Largest reduction occurred in Q1 2025, reducing 6,452 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +51,706 | Add 152.48% | 85,617 | $397.65 |
| Q3 2025 | +33,911 | New Buy | 33,911 | $456.00 |
| Q1 2025 | -6,452 | Sold Out | 0 | $0.00 |
| Q4 2024 | +4,450 | Add 222.28% | 6,452 | $235.31 |
| Q3 2024 | +2,002 | New Buy | 2,002 | $275.03 |
| Q1 2024 | -1,951 | Sold Out | 0 | $0.00 |
| Q4 2023 | +65 | Add 3.45% | 1,951 | $191.41 |
| Q3 2023 | +90 | Add 5.01% | 1,886 | $177.10 |
| Q2 2023 | +541 | Add 43.11% | 1,796 | $189.94 |
| Q1 2023 | +1,255 | New Buy | 1,255 | $200.32 |
| Q4 2022 | -1,283 | Sold Out | 0 | $0.00 |
| Q3 2022 | -229 | Reduce 15.15% | 1,283 | $200.31 |
| Q2 2022 | +1,512 | New Buy | 1,512 | $146.16 |
| Q4 2021 | -2,234 | Sold Out | 0 | $0.00 |
| Q3 2021 | -3,865 | Reduce 63.37% | 2,234 | $188.90 |
| Q2 2021 | +6,099 | New Buy | 6,099 | $169.54 |
Ray Dalio's Alnylam Pharmaceuticals Investment FAQs
Ray Dalio first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q2 2021, acquiring 6,099 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Alnylam Pharmaceuticals, Inc. (ALNY) for 16 quarters since Q2 2021.
Ray Dalio's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q4 2025, adding 85,617 shares worth $34.05 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 85,617 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $34.05 M.
As of the Q4 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.12% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 85,617 shares, as reported at the end of Q4 2025.